Publikationen 2005

  1. Classen CF, Teigler-Schlegel A, Rottgers S, Reinhardt D, Dohner K, Debatin KM: AML bearing the translocation t(11;17)(q23;q21): involvement of MLL and a region close to RARA, with no differentiation response to retinoic acid. Ann Hematol 2005;84:774-780. www.ncbi.nlm.nih.gov/pubmed/16044313
  2. Classen CF, Behnisch W, Reinhardt D, Koenig M, Moller P, Debatin KM: Spontaneous complete and sustained remission of a rearrangement CBP (16p13)-positive disseminated congenital myelosarcoma. Ann Hematol 2005;84:274-275. www.ncbi.nlm.nih.gov/pubmed/15605245
  3. Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M: AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005;19:1355-1360. www.ncbi.nlm.nih.gov/pubmed/15920490
  4. Creutzig U, Henze G: Grundlagen der Therapie von Tumoren und malignen Systemerkrankungen des Kindes; in Reinhardt D, Böhles H, Creutzig U, Kiess W, Korinthenberg R, Michalk D, Poets CF, Schmaltz AA, Schmittenbecher P, Weiß M, (eds): Leitlinien Kinderheilkunde und Jugendmedizin. Deutsche Gesellschaft für Kinder- und Jugendmedizin e.V. Elsevier Urban & Fischer Verlag, 2005, pp 11-15.
  5. Creutzig U, Henze G: Organisationsstruktur der Pädiatrischen Onkologie und derzeitiger Stand der Qualitätssicherung; in Reinhardt D, Böhles H, Creutzig.U., Kiess W, Korinthenberg R, Michalk D, Poets CF, Schmaltz AA, Schmittenbecher P, Weiß M, (eds): Leitlinien Kinderheilkunde und Jugendmedizin. Deutsche Gesellschaft für Kinder- und Jugendmedizin e.V. München, Jena, Elsevier Urban & Fischer Verlag, 2005, pp 7-9.
  6. Creutzig U, Zimmermann M, Hannemann J, Krämer I, Pfistner B, Herold R, Henze G: Quality management for clinical trials within the German Competence Network Paediatric Oncology and Haematology. Onkologie 2005;28:333-336. www.ncbi.nlm.nih.gov/pubmed/15933421
  7. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, Jurgens H, Kabisch H, Reiter A, Riehm H, Gadner H, Schellong G: Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005;19:2030-2042. www.ncbi.nlm.nih.gov/pubmed/16304570
  8. Goemans BF, Zwaan C, Martinelli S, Harrell P, de Lange D, Carta C, Reinhardt D, Hahlen K, Creutzig U, Tartaglia M, Heinrich MC, Kaspers GJ: Differences in the prevalence of PTPN11 mutations in FAB M5 paediatric acute myeloid leukaemia. Br J Haematol 2005;130:801-803. www.ncbi.nlm.nih.gov/pubmed/16115145
  9. Goemans BF, Zwaan CM, Harlow A, Loonen AH, Gibson BE, Hahlen K, Reinhardt D, Creutzig U, Heinrich MC, Kaspers GJ: In vitro profiling of the sensitivity of pediatric leukemia cells to Tipifarnib (ZarnestraTM): Identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood 2005;106:3532-3537. www.ncbi.nlm.nih.gov/pubmed/16051737
  10. Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S, Loonen AH, Hahlen K, Reinhardt D, Creutzig U, Kaspers GJ, Heinrich MC: Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005;19:1536-1542. www.ncbi.nlm.nih.gov/pubmed/16015387
  11. Hubeek I, Peters GJ, Broekhuizen AJ, Talianidis I, Sigmond J, Gibson BE, Creutzig U, Giaccone G, Kaspers GJ: Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours. J Clin Pathol 2005;58:695-699. www.ncbi.nlm.nih.gov/pubmed/15976334
  12. Hubeek I, Peters GJ, Broekhuizen AJ, Sargent J, Gibson BE, Creutzig U, Kaspers GJ: Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia. Br J Haematol 2005;131:219-222. www.ncbi.nlm.nih.gov/pubmed/16197453
  13. Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, Wering ER, Gibson BE, Creutzig U, Zwaan CM, Cloos J, Kuik DJ, Pieters R, Kaspers GJ: The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 2005;93:1388-1394. www.ncbi.nlm.nih.gov/pubmed/16333246
  14. Kaspers GJ, Creutzig U: Pediatric acute myeloid leukemia: international progress and future directions. Leukemia 2005;19:2025-2029. www.ncbi.nlm.nih.gov/pubmed/16304569
  15. Langebrake C, Creutzig U, Reinhardt D: Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr 2005;217:126-134. www.ncbi.nlm.nih.gov/pubmed/15858703
  16. Langebrake C, Brinkmann I, Teigler-Schlegel A, Creutzig U, Griesinger F, Puhlmann U, Reinhardt D: Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. Cytometry B Clin Cytom 2005;63B:1-9. www.ncbi.nlm.nih.gov/pubmed/15624201
  17. Lehrnbecher T, Bernig T, Hanisch M, Koehl U, Behl M, Reinhardt D, Creutzig U, Klingebiel T, Chanock SJ, Schwabe D: Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia. Leukemia 2005;19:1745-1750. www.ncbi.nlm.nih.gov/pubmed/16107886
  18. Masjosthusmann K, Bielack SS, Kohler G, Florax A, Schiborr M, Bruch J, Reinhardt D, Kuhn N, Paulussen M, Jürgens H: Concomitant Ewing sarcoma and acute lymphoblastic leukemia in a 5-year-old girl. Pediatr Blood Cancer 2005;45:846-849. www.ncbi.nlm.nih.gov/pubmed/15926159
  19. Puhlmann U, Ziemann C, Ruedell G, Vorwerk H, Schaefer D, Langebrake C, Schuermann P, Creutzig U, Reinhardt D: Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J Pharmacol Exp Ther 2005;312:346-354. www.ncbi.nlm.nih.gov/pubmed/15501994
  20. Reinhardt D, Diekamp S, Langebrake C, Ritter J, Stary J, Dworzak M, Schrauder A, Zimmermann M, Fleischhack G, Ludwig WD, Harbott J, Creutzig U: Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment. Leukemia 2005;19:1495-1496. www.ncbi.nlm.nih.gov/pubmed/15920489
  21. Stam RW, Hubeek I, den Boer ML, Buijs-Gladdines JG, Creutzig U, Kaspers GJ, Pieters R: MLL gene rearrangements have no direct impact on Ara-C sensitivity in infant acute lymphoblastic leukemia and childhood M4/M5 acute myeloid leukemia. Leukemia 2005. www.ncbi.nlm.nih.gov/pubmed/16307022
Suchen
Benutzeranmeldung